Abstract
Chilblain lupus erythematosus is a rare form of cutaneous lupus erythematosus characterized by bluish red infiltrates in acral locations of the body mostly affecting middle-aged women. We recently described a familial form of chilblain lupus manifesting in early childhood caused by a heterozygous mutation in the TREX1 gene, which encodes a 3′-5′ DNA exonuclease. Thus, familial chilblain lupus represents the first monogenic form of cutaneous lupus erythematosus. Here we describe the unusual clinical course of this newly defined genodermatosis in an 18-year-old female member of the family in which familial chilblain lupus was originally described.
References
1.
Kuhn A, Sticherling M, Bonsmann G: Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 2007;5:1124–1137.
2.
Su WP, Perniciaro C, Rogers RS III, White JW Jr: Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis 1994;54:395–399.
3.
Bouaziz JD, Barete S, Le PF, Amoura Z, Piette JC, Frances C: Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases. Lupus 2007;16:163–167.
4.
Allegue F, Alonso ML, Rocamora A, Ledo A: Chilblain lupus erythematosus and antiphospholipid antibody syndrome. J Am Acad Dermatol 1988;19:908–910.
5.
Franceschini F, Calzavara-Pinton P, Valsecchi L, Quinzanini M, Zane C, Facchetti F, Airo P, Cattaneo R: Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. Adv Exp Med Biol 1999;455:167–171.
6.
Lee-Kirsch MA, Gong M, Schulz H, Ruschendorf F, Stein A, Pfeiffer C, Ballarini A, Gahr M, Hubner N, Linne M: Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006;79:731–737.
7.
Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K, Pfeiffer C, Hollis T, Gahr M, Perrino FW, Lieberman J, Hubner N: A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 2007;85:531–537.
8.
Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, Robins P, Harvey S, Hollis T, O’Hara A, Herrick AL, Bowden AP, Perrino FW, Lindahl T, Barnes DE, Crow YC: Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007;80:811–815.
9.
Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B, Perrino FW, Lieberman J: The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell 2006;23:133–142.
10.
Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, Black DN, van Bokhoven H, Brunner HG, Hamel BC, Corry PC, Cowan FM, Frints SG, Klepper J, Livingston JH, Lynch SA, Massey RF, Meritet JF, Michaud JL, Ponsot G, Voit T, Lebon P, Bonthron DT, Jackson AP, Barnes DE, Lindahlet T: Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006;38:917–920.
11.
Kolivras A, Aeby A, Crow YJ, Rice GI, Sass U, Andre J: Cutaneous histopathological findings of Aicardi-Goutieres syndrome, overlap with chilblain lupus. J Cutan Pathol 2008;35:774–778.
12.
Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, Liszewski MK, Barilla-Labarca ML, Terwindt GM, Kasai Y, McLellan M, Grand MG, Vanmolkot KR, de Vries B, Wan J, Kane MJ, Mamsa H, Schafer R, Stam AH, Haan J, de Jong PT, Storimans CW, van Schooneveld MJ, Oosterhuis JA, Gschwendter A, Dichgans M, Kotschet KE, Hodgkinson S, Hardy TA, Delatycki MB, Hajj-Ali RA, Kothari PH, Nelson SF, Frants RR, Baloh RW, Ferrari MD, Atkinsonet JP: C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007;39:1068–1070.
13.
Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U, Bailey SL, Witte T, Vyse TJ, Kere J, Pfeiffer C, Harvey S, Wong A, Koskenmies S, Hummel O, Rohde K, Schmidt RE, Dominiczak AF, Gahr M, Hollis T, Perrino FW, Lieberman J, Hubner N: Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007;39:1065–1067.
14.
Kanda N, Tsuchida T, Watanabe T, Tamaki K: Cutaneous lupus mucinosis: a review of our cases and the possible pathogenesis. J Cutan Pathol 1997;24:553–558.
15.
Weigand DA, Burgdorf WH, Gregg LJ: Dermal mucinosis in discoid lupus erythematosus: report of two cases. Arch Dermatol 1981;117:735–738.
16.
Lipsker D: Classification of specific cutaneous manifestations in patients with lupus erythematosus: a time for change? The concept of dermal lupus erythematosus. Dermatology 2006;212:324–326.
17.
Lipsker D, Mitschler A, Grosshans E, Cribier B: Could Jessner’s lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases. Dermatology 2006;213:15–22.
18.
Yang YG, Lindahl T, Barnes DE: Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007;131:873–886.
19.
Medzhitov R, Janeway CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91:295–298.
20.
Doutre MS, Beylot C, Beylot J, Pompougnac E, Royer P: Chilblain lupus erythematosus: report of 15 cases. Dermatology 1992;184:26–28.
21.
Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, Heubner G, Lee-Kirsch MA, Gahr M: Chilblain lupus erythematosus – a review of literature. Clin Rheumatol 2008;27:949–954.
22.
Dorak MT, Shao W, Machulla HK, Lobashevsky ES, Tang J, Park MH, Kaslow RA: Conserved extended haplotypes of the major histocompatibility complex: further characterization. Genes Immun 2006;7:450–467.
23.
Tsao BP: Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 2004;16:513–521.
24.
Agnello V, Gell J, Tye MJ: Partial genetic deficiency of the C4 component of complement in discoid lupus erythematosus and urticaria/angioedema. J Am Acad Dermatol 1983;9:894–898.
25.
Uter W, Proksch E, Schauder S: Chilblain lupus erythematosus. Hautarzt 1988;39:602–605.
26.
Rustin MH, Newton JA, Smith NP, Dowd PM: The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol 1989;120:267–275.
27.
Millard LG, Rowell NR: Chilblain lupus erythematosus (Hutchinson): a clinical and laboratory study of 17 patients. Br J Dermatol 1978;98:497–506.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
